On the recordJuly 12, 2017
The FDA Reauthorization Act we are considering today provides the FDA the resources it needs to ensure innovative and lifesaving drugs and medical devices are brought to the market in a safe and expedient manner, while providing transparency and certainty to manufacturers. Further, the device inspection and regulatory improvements title reflects language I introduced with Representatives Brooks, Peters, and Butterfield, which sets forth a risk-based approach to medical device establishment inspections and improves predictability for scheduled inspections, among other provisions. Mr. Speaker, I urge my colleagues to support this legislation. I look forward to moving it through Congress and sending it to the President's desk.
